MPC Therapeutics

Mitochondrial reprogramming to treat cancer, kidney, and neurodegenerative diseases.

Founded in 2020 as a spin-off from the University of Geneva, MPC Therapeutics is developing small molecules targeting the Mitochondrial Pyruvate Carrier (MPC), a crucial regulator of cellular energy. By focusing on this key metabolic target, we aim to address critical unmet medical needs in cancer immunotherapy, kidney diseases, and neurodegeneration. We are proud to be the first Swiss startup selected to join Johnson & Johnson’s JLABS incubator.